Pfizer Corporation

Harvard College

Daniel W Kung

Kimberly O Cameron

Samit Kumar Bhattacharya

Dilinie Fernando

John William Benbow

Philip Albert Carpino

Andrew G Myers

Kentaro Futatsugi

David Hepworth

Travis T Wager

Meihua Mike Tu

Kevin James Filipski

Matthew Scott Dowling

Kim F McClure

Aaron Smith

Allyn T Londregan

Shawn Cabral

Margaret Y Chu-Moyer

Markus Boehm

Suvi Orr

Esther C Lee

David Christopher Ebner

Jian Wang

Alleyn T Plowright

Kay Ahn

Brian Lanman

Suvi T M Simila

Derivatives of purine, 3H-imidazo[4,5-b]pyrimidine and 1H-imidazo[4,5-d]pyrazine of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.

Diacylglycerol acyltransferase 2 inhibitors

The present invention relates to indole and indazole compounds of Formula (I) that activate 5' adenosine monophosphate-activated protein kinase (AMPK). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating or preventing diseases, conditions, or disorders ameliorated by activation of AMPK.

Indole and indazole compounds that activate AMPK

The present invention provides a compound of Formula (I) or a pharmaceutically salt thereof wherein R, R, Ra, L, Z, Zand Zare as defined herein, that act as Ghrelin antagonists or inverse agonists; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by the antagonism of the Ghrelin receptor.

2,3-dihydro-1H-inden-1-yl-2,7-diazaspiro[3.5] nonane derivatives

The present invention provides compounds of formula (I) the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers, and prodrugs, wherein R, R, and Rare as defined herein; pharmaceutical compositions thereof; combinations thereof; and uses thereof in the treatment of, inter alia, conditions, diseases, and symptoms including, inter alia, Alzheimer's Disease, cancer, dementia, depression, diabetes, hair loss, schizophrenia, and stroke. 

Aminopyrazole derivatives as GSK-3 inhibitors

The present invention provides compounds of formula (I) the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers, and prodrugs, wherein R, Rand Rare as defined herein; pharmaceutical formulations thereof; and use thereof in the treatment of, inter alia, conditions, diseases, and symptoms such as bipolar disorder, diabetes, dementia, Alzheimer's Disease, stroke, schizophrenia, depression, hair loss, and cancer.

Pyrazolo[3,4-b]pyridin-6-ones as GSK-3 inhibitors

The present invention provides compounds of formula (I) the prodrugs thereof, and the pharmaceutically acceptable salts of the compounds and prodrugs, wherein R, R, R, and Rare as defined herein; pharmaceutical compositions thereof; and uses thereof.

Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines

Saframycins, analogues and uses thereof

Growing community of inventors

Salem, CT, United States of America

Daniel W Kung